BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » iPS Cells » Page 6

Novo Nordisk Ends $598M Heartseed Partnership to Refocus Strategic Priorities

By Leave a Comment

Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically.  The cancelled partnership, originally launched in 2021, was focused on developing an allogeneic induced pluripotent stem cell (iPSC)-derived therapy for heart failure called “HS-001”.

Novo’s decision to terminate the deal, announced by Heartseed in a securities filing this week, was attributed to “strategic reviews and business shifts” under the company’s new CEO, Mike Doustdar. The move ends a four-year partnership that once represented a bold leap into regenerative medicine for Novo Nordisk.  [Read more…]

GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL:
A Cost-Optimized Approach

By Leave a Comment

Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.

This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing. [Read more…]

Trailhead Biosystems Puts iPSCs on a New Path

By Leave a Comment

Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research. [Read more…]

4 Major Areas of Commercialization for iPS Cells

By Leave a Comment

Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type.  In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.

In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”

[Read more…]

Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery

By Leave a Comment

Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data analysis to de-risk and accelerate therapeutic development.

SEATTLE — Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio’s human-relevant platforms into global clinical success. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0